Skip to content

Study · Animal study (in vivo) · mouse · 1999

9 results

A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.

Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D, Stancic-Rokotov D, Separovic J, Seiwerth S, Grabarevic Z, Rucman R, Petek M and 12 more

Show all authors

Ziger T, Sebecic B, Zoricic I, Turkovic B, Aralica G, Perovic D, Duplancic B, Lovric-Bencic M, Rotkvic I, Mise S, Jagic V, Hahn V

Journal of physiology, Paris1 Dec 1999Cited by 37 (Europe PMC)

PMID10672997 (opens in a new tab)DOI10.1016/s0928-4257(99)00119-9 (opens in a new tab)PepBankPUB-10672997
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, BPC‑157 improved the impaired somatosensory orientation.

    In plain wordsIn mice given the toxin MPTP, BPC‑157 improved impaired orientation.

    Peptide
    BPC-157
    Outcome
    IncreaseMPTP-impaired somatosensory orientation
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1.50 µg or 15.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    BPC 157 strongly improved the MPTP-impaired somatosensory orientation
    1 context sentence
    Summary · context
    Parkinsongenic agents, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30.0 mg x kg(-1)b.w. i.p. once daily for 6d, and after 4d once 50.0 mg x kg(-1)b.w. i.p.) or reserpine (5.0 mg x kg(-1)b.w. i.p.) were applied i.p. BPC 157 (1.50 microg or 15.0 ng x kg(-1)b.w. i.p.) was applied 15 min before…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, BPC‑157 reduced MPTP-induced hyperactivity.

    In plain wordsIn mice given the toxin MPTP, BPC‑157 reduced overactivity.

    Peptide
    BPC-157
    Outcome
    DecreaseMPTP-induced hyperactivity
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1.50 µg or 15.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    reduced the MPTP-induced hyperactivity
    1 context sentence
    Summary · context
    Parkinsongenic agents, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30.0 mg x kg(-1)b.w. i.p. once daily for 6d, and after 4d once 50.0 mg x kg(-1)b.w. i.p.) or reserpine (5.0 mg x kg(-1)b.w. i.p.) were applied i.p. BPC 157 (1.50 microg or 15.0 ng x kg(-1)b.w. i.p.) was applied 15 min before…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, BPC‑157 reduced MPTP motor abnormalities (tremor, akinesia, catalepsy) that were prominent in saline controls.

    In plain wordsIn mice given the toxin MPTP, BPC‑157 reduced tremor, slowed movement and catalepsy seen in controls.

    Peptide
    BPC-157
    Outcome
    DecreaseMPTP motor abnormalities (tremor, akinesia, catalepsy)
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1.50 µg or 15.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    MPTP-motor abnormalities (tremor, akinesia, catalepsy -otherwise very prominent in saline control
    1 context sentence
    Summary · context
    Parkinsongenic agents, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30.0 mg x kg(-1)b.w. i.p. once daily for 6d, and after 4d once 50.0 mg x kg(-1)b.w. i.p.) or reserpine (5.0 mg x kg(-1)b.w. i.p.) were applied i.p. BPC 157 (1.50 microg or 15.0 ng x kg(-1)b.w. i.p.) was applied 15 min before…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, BPC‑157 led to almost complete abolition of the otherwise regularly lethal course of MPTP treatment seen in controls.

    In plain wordsIn mice given the toxin MPTP, BPC‑157 almost completely prevented the deaths seen in controls.

    Peptide
    BPC-157
    Outcome
    DecreaseLethal course of MPTP treatment
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Mortality · Nervous system and cognition
    Studied dose
    1.50 µg or 15.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    leading to almost complete abolition of otherwise regularly lethal course of MPTP treatment in controls.
    1 context sentence
    Summary · context
    Parkinsongenic agents, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30.0 mg x kg(-1)b.w. i.p. once daily for 6d, and after 4d once 50.0 mg x kg(-1)b.w. i.p.) or reserpine (5.0 mg x kg(-1)b.w. i.p.) were applied i.p. BPC 157 (1.50 microg or 15.0 ng x kg(-1)b.w. i.p.) was applied 15 min before…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated mice, BPC‑157 given before reserpine prevented the development of catalepsy.

    In plain wordsIn mice given reserpine, BPC‑157 given beforehand prevented catalepsy.

    Peptide
    BPC-157
    Outcome
    DecreaseReserpine-induced catalepsy, prevention
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10.0 µg or 10.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    BPC 157 strongly prevented the development of otherwise very prominent catalepsy
    1 context sentence
    Summary · context
    In reserpine studies, BPC 157 (10.0 microg or 10.0 ng x kg(-1)b.w. i.p.) was given either 15 min before reserpine or in the already established complete catalepsy 24 h thereafter.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated mice, BPC‑157 given 24 h after reserpine reversed the established catalepsy.

    In plain wordsIn mice given reserpine, BPC‑157 given later reversed existing catalepsy.

    Peptide
    BPC-157
    Outcome
    DecreaseEstablished reserpine catalepsy, reversal
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10.0 µg or 10.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    when applied 24 h thereafter reversed the established catalepsy.
    1 context sentence
    Summary · context
    In reserpine studies, BPC 157 (10.0 microg or 10.0 ng x kg(-1)b.w. i.p.) was given either 15 min before reserpine or in the already established complete catalepsy 24 h thereafter.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated mice, BPC‑157 pre-treatment reduced reserpine-induced hypothermia.

    In plain wordsIn mice given reserpine, BPC‑157 given beforehand reduced the drop in body temperature.

    Peptide
    BPC-157
    Outcome
    DecreaseReserpine-induced hypothermia, pre-treatment
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10.0 µg or 10.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    a reduction of reserpine-hypothermy (BPC 157 pre-treatment)
    1 context sentence
    Summary · context
    In reserpine studies, BPC 157 (10.0 microg or 10.0 ng x kg(-1)b.w. i.p.) was given either 15 min before reserpine or in the already established complete catalepsy 24 h thereafter.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated mice, BPC‑157 post-treatment reversed the further prominent temperature fall.

    In plain wordsIn mice given reserpine, BPC‑157 given afterwards reversed a further drop in body temperature.

    Peptide
    BPC-157
    Outcome
    DecreaseReserpine-induced temperature fall, post-treatment
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10.0 µg or 10.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    reversal of further prominent temperature fall (BPC 157 post-treatment) have been consistently observed.
    1 context sentence
    Summary · context
    In reserpine studies, BPC 157 (10.0 microg or 10.0 ng x kg(-1)b.w. i.p.) was given either 15 min before reserpine or in the already established complete catalepsy 24 h thereafter.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice treated with MPTP, BPC‑157 in either regimen strongly attenuated the stomach lesions that MPTP otherwise caused.

    In plain wordsIn mice given the toxin MPTP, BPC‑157 reduced stomach lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseMPTP-induced stomach lesions
    Study

    mousen: not reported in source

    MPTP and reserpine Parkinson's disease models
    Comparator
    Saline control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    1.50 µg or 15.0 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, given in either regimen, pentadecapeptide BPC 157 strongly attenuated the stomach lesions in mice that otherwise consistently appeared in mice treated with the parkinsogenic neurotoxin MPTP.
    1 context sentence
    Summary · context
    Parkinsongenic agents, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30.0 mg x kg(-1)b.w. i.p. once daily for 6d, and after 4d once 50.0 mg x kg(-1)b.w. i.p.) or reserpine (5.0 mg x kg(-1)b.w. i.p.) were applied i.p. BPC 157 (1.50 microg or 15.0 ng x kg(-1)b.w. i.p.) was applied 15 min before…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.